Aurobindo reports record Q2 revenue up 24% to Rs 10,263 crore

Aurobindo Pharma Limited (Aurobindo) reported record revenue from operations of Rs 10,263 crore for Q2FY27, up 23.9% from Q2FY26, led by 25.2% growth in US revenue to Rs 4,555 crore and 27.5% growth in Europe revenue to Rs 3,161 crore. Net profit increased 32.5% to Rs 1,124 crore.

How did Aurobindo perform in Q2FY27?

Aurobindo increased revenue from operations to Rs 10,263 crore in Q2FY27, from Rs 8,286 crore in Q2FY26 and Rs 9,150 crore in Q1FY27. That represented year-on-year growth of 23.9% and sequential growth of 12.2%. Total formulations revenue reached Rs 9,102 crore, up 24.2% from Rs 7,325 crore a year earlier and 12.4% from Rs 8,101 crore in the preceding quarter.

Aurobindo's net profit grew faster than revenue, rising to Rs 1,124 crore from Rs 848 crore in Q2FY26 and Rs 1,032 crore in Q1FY27. Earnings before interest, tax, depreciation and amortisation, or EBITDA, before foreign exchange and other income, rose 28.5% year on year to Rs 2,156 crore. Profit before tax, before the share of profit or loss of joint ventures, increased 32.7% to Rs 1,691 crore.

What drove Aurobindo's Q2FY27 revenue growth?

Aurobindo's US and Europe businesses provided the largest additions to Q2FY27 revenue. US revenue rose by Rs 917 crore year on year to Rs 4,555 crore, while Europe revenue increased by Rs 681 crore to Rs 3,161 crore. Together, the two geographies contributed Rs 7,716 crore, or about three quarters, of Q2FY27 consolidated revenue of Rs 10,263 crore.

Aurobindo attributed US growth to successful integration, base-business growth and new launches. It launched 10 products in the US market, including gAdvair and ADQUEY, which it identified as its first new chemical entity. Europe accounted for 31% of consolidated revenue, while its revenue rose 7.6% sequentially from Rs 2,937 crore in Q1FY27 to Rs 3,161 crore in Q2FY27.

Growth Markets formulations revenue increased 16.3% year on year to Rs 1,026 crore but fell 3.5% sequentially from Rs 1,063 crore. Antiretroviral, or ARV, revenue was Rs 359 crore, up 10.2% from Q2FY26 and 8.7% from Q1FY27. Aurobindo said quarterly variation in the ARV business was driven by tender opportunities.

How did Aurobindo's businesses contribute to revenue?

Aurobindo generated Rs 9,102 crore from formulations and Rs 1,162 crore from active pharmaceutical ingredients, or API, in Q2FY27. Formulations rose 24.2% year on year, compared with API growth of 20.9% from Rs 961 crore in Q2FY26. API contributed 11% of consolidated revenue, according to the company.

Within API, beta-lactam revenue rose 24.8% year on year to Rs 858 crore, while non-beta-lactam revenue increased 11.3% to Rs 304 crore. Sequentially, beta-lactam revenue grew 7.3% from Rs 800 crore and non-beta-lactam revenue increased 21.7% from Rs 250 crore. Aurobindo attributed API growth to a favourable business mix.

Did Aurobindo's profitability improve in Q2FY27?

Aurobindo's EBITDA margin before foreign exchange and other income expanded to 21.0% in Q2FY27, from 20.3% in Q2FY26 and 20.6% in Q1FY27. The year-on-year increase was 75 basis points, with one basis point equal to one-hundredth of a percentage point. EBITDA increased by Rs 478 crore year on year, compared with a Rs 1,977 crore increase in revenue.

Aurobindo reported basic and diluted earnings per share of Rs 19.57 for Q2FY27. Research and development expenditure was Rs 376 crore, compared with Rs 344 crore in Q1FY27, an increase of Rs 32 crore. The company also declared an interim dividend of Rs 7 per share alongside the quarterly result.

What is Aurobindo's US product approval position?

Aurobindo received final approval from the US Food and Drug Administration, or USFDA, for 12 products in Q2FY27. As of September 30, 2026, it had cumulatively filed 900 abbreviated new drug applications, or ANDAs, with the USFDA and received 747 final approvals and 35 tentative approvals.

Aurobindo's US revenue rose 20.8% sequentially, from Rs 3,770 crore in Q1FY27 to Rs 4,555 crore in Q2FY27, alongside the 10 US product launches. The 12 final approvals add to the 747 cumulative final approvals, while the 35 tentative approvals remain a separate regulatory category in the company's disclosed USFDA portfolio.

Conclusion

Aurobindo's Q2FY27 result combined record revenue of Rs 10,263 crore with net profit of Rs 1,124 crore and a 21.0% EBITDA margin. US and Europe revenue together increased by Rs 1,598 crore from Q2FY26, while formulations and API revenue rose 24.2% and 20.9%, respectively, showing growth across the company's principal businesses.

The next disclosed event is Aurobindo's earnings call scheduled for 8:30 AM Indian Standard Time on November 5, 2026. Participants may seek further detail on the contribution from 10 US launches, the 12 final USFDA approvals, and whether Growth Markets revenue can recover from its 3.5% sequential decline in Q2FY27.